Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics

Advanced Drug Delivery Reviews

Volumn 39, Issue 1-3, 1999, Pages 117-151

  Tan, Xiaolei ^a   Chu, Chung K ^a   Boudinot, F Douglas ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

2',3' Dideoxynucleoside analog; Anti HIV; Cellular pharmacology; Nucleotide analog; Pharmacokinetics; Prodrug; Reverse transcriptase

Indexed keywords

ANTIBIOTICS; BIOSYNTHESIS; ENZYMES; PHARMACOKINETICS; VIRUSES;

CELLULAR PHARMACOLOGY; HUMAN IMMUNODEFICIENCY VIRUS (HIV);

CONTROLLED DRUG DELIVERY;

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYADENOSINE DERIVATIVE; DEOXYURIDINE DERIVATIVE; DIDANOSINE; DIHYDROPYRIDINE DERIVATIVE; DINUCLEOTIDE; LAMIVUDINE; NUCLEOSIDE ANALOG; PHOSPHOLIPID DERIVATIVE; PRODRUG; STAVUDINE; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032823876     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00023-X     Document Type: Article

References (239)

1. De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses. 8:1992;119-134.
2. Balzarini J., Pauwels R., Baba M., Herdewijn P., De Clercq E., Broder S., Johns D.G. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochem. Pharmacol. 37:1988;897-903.
3. Shirasaka T., Chokekijchal S., Yamada A., Gosselin G., Imbach J.-L., Mitsuya H. Comparative analysis of anti-human immunodeficiency virus type I activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 39:1995;2555-2559.
4. Gao W.-Y., Agbaria R., Driscoll J.S., Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:1994;12633-12638.
5. Inoue T., Tsushita K., Itoh T., Ogura M., Hotta T., Saneyoshi M., Yoshida S., Saitoh H., Tomoda Y., Nagai Y. In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus. Antimicrob. Agents Chemother. 33:1989;576-579.
6. Dornsife R.E., Averett D.R. In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob. Agents Chemother. 40:1996;514-519.
7. Chen C.-H., Vazquez-Padua M., Cheng Y.-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39:1991;625-628.
8. Faraj A., Fowler D.A., Bridges E.G., Sommadossi J.-P. Effects of 2′,3′-dideoxynucleosides on protiteration and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38:1994;924-930.
9. Plagemann P.G.W., Wohlhueter R.M., Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta. 947:1988;405-443.
10. Domin B.A., Mahony W.B., Zimmerman T.P. Membrane permeation mechanisms of 2′,3′-dideoxynucleosides. Biochem. Pharmacol. 46:1993;725-729.
11. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. USA. 83:1986;1911-1915.
12. Herdewijn P., Balzarini J., De Clercq E., Pauwels R., Baba M., Broder S., Vanderhaeghe H. 3′-substituted 2′,3′-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. J. Med. Chem. 30:1987;1270-1278.
13. Balzarini J., Baba M., Pauwels R., Herdewijn P., De Clercq E. Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem. Pharmacol. 37:1988;2847-2856.
14. Balzarini J., Baba M., Pauwels R., Herdewijn P., Wood S.G., Robins M.J., De Clercq E. Potent and selective activity of 3′-azido-2,6-diaminopurine-2′,3′-dideoxyriboside, 3′-fluoro-2,6-diaminopurine-2′,3′-dideoxyriboside, and 3′-fluoro-2′,3′-dideoxyguanosine against human immunodeficiency virus. Mol. Pharmacol. 33:1988;243-249.
15. Herdewijn P., Balzarini J., Baba M., Pauwels R., Van Aerschot A., Jassen G., De Clercq E. Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides. J. Med. Chem. 31:1988;2040-2048.
16. Watanabe K.A., Harada K., Zeidler J., Matulic-Adamic J., Takahashi K., Ren W.-Y., Cheng L.-C., Fox J.J., Chou T.-C., Zhu Q.-Y., Polsky B., Gold J.W.M., Armstrong D. Synthesis and anti-HIV activity of 2′-'up'-fluoro analogues of active anti-AIDS nucleosides 3′-azido-3′deoxythymidine (AZT) and 2′,3′-dideoxycytidine (DDC). J. Med. Chem. 33:1990;2145-2150.
17. Huang J.-H., Chen L.-L., Wang L., Kim M.-H., Warshaw J.A., Armstrong D., Zhu Q.-Y., Chou T.-C., Watanabe K.A., Matulic-Adamic J., Su T.-L., Fox J.J., Polsky B., Baron P.A., Gold J.W.M., Hardy W.D., Zuckerman E. Fluorinated sugar analogues of potential anti-HIV-1 nucleosides. J. Med. Chem. 34:1991;1640-1646.
18. Warshaw J.A., Watanabe K.A. 2′-azido-2′,3′-dideoxypyrimidine nucleosides. Synthesis and antiviral activity against human immunodeficiency virus. J. Med. Chem. 33:1990;1663-1666.
19. Hiebl J., Zbiral E., Balzarini J., De Clercq E. Synthesis and antiretrovirus properties of 5′-isocyano-5′-deoxythymidine, 5′-isocyano-2′,5′-dideoxyuridine, 3′-azido-5′-isocyano-3′,5′-dideoxythymidine, and 3′-azido-5′-isocyano-2′,3′,5′-trideoxyuridine. J. Med. Chem. 34:1991;1426-1430.
20. Jie L., Van Aerschot A., Balzarini J., Jassen G., Busson R., Hoogmartens J., De Clercq E., Herdewijn P. 5′-O-phosphonomethyl-2′,3′-dideoxynucleosides: synthesis and anti-HIV activity. J. Med. Chem. 33:1990;2481-2487.
21. Kumar R., Wang L., Wiebe L.I., Knaus E.E. Synthesis, in vitro biological stability, and anti-HIV activity of 5-halo-6-alkoxy (or azido)-5,6-dihydro-3′-azido-3′-deoxythymidine diastereomers as potential prodrugs to 3′-azido-3′-deoxythymidine (AZT). J. Med. Chem. 37:1994;4297-4306.
22. Kumar R., Wang L., Wiebe L.I., Knaus E.E. Synthesis and antiviral (HIV-1, HBV) activities of 5-halo-6-methyoxy (or azido)-5, 6-dihydro-3′-fluoro-3′-deoxythymidine diastereomers. Potential prodrugs to 3′-fluoro-3′-deoxythymidine. J. Med. Chem. 37:1994;3554-3560.
23. Rosowsky A., Solan V.C., Sodroski J.G., Ruprecht R.M. Synthesis of the 2-chloro analogues of 3′-deoxyadenosine, 2′,3′-dideoxyadenosine, and 2′,3′-didehydro-2′,3′-dideoxyadenosine as potential antiviral agents. J. Med. Chem. 32:1989;1135-1140.
24. Van Aerschot A., Herdewijn P., Balzarini J., Pauwels R., De Clercq E. 3′-fluoro-2′,3′-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2′- and 3′-fluorinated 2′,3′-dideoxynucleoside analogues. J. Med. Chem. 32:1989;1743-1749.
25. Balzarini J., Van Aerschot A., Herdewijn P., De Clercq E. 5-Chloro-substituted derivatives of 2′,3′-didehydro-2′,3′-dideoxyuridine, 3′-fluoro-2′,3′-dideoxyuridine as anti-HIV agents. Biochem. Pharmacol. 38:1989;869-874.
26. Van Aerschot A., Everaert D., Balzarini J., Augustyns K., Jie L., Jassen G., Peeters O., Blaton N., De Ranter C., De Clercq E., Herdewijn P. Synthesis and anti-HIV evaluation of 2′,3′-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2′,3′-dideoxynucleosides. J. Med. Chem. 33:1990;1833-1839.
27. Shirasaka T., Murakami K., Ford H. Jr., Kelly J.A., Yoshioka H., Kojima E., Broder S., Mitsuya H. Lipophilic halogenated congeners of 2′,3′-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA. 87:1990;9426-9430.
28. Lin T.-S., Luo M.-Z., Liu M.-C., Pai S.B., Dutschman G.E., Cheng Y.-C. Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and Hepatitis B virus (HBV). J. Med. Chem. 37:1994;798-803.
29. Lin T.-S., Luo M.-Z., Liu M.-C., Zhu Y.-L., Gullen E., Dutschman G.E., Cheng Y.-C. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39:1996;1757-1759.
30. Huryn D.M., Sluboski B.C., Tam S.Y., Weigele M., Sim I., Anderson B.D., Mitsuya H., Broder S. Synthesis and anti-HIV activity of isonucleosides. J. Med. Chem. 35:1992;2347-2354.
31. Mitsuya H., Weinhold K.J., Furman P.A., St. Clair M.H., Lehrman S.N., Gallo R.C., Bolognesi D., Barry D.W., Broder S. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA. 82:1985;7096-7100.
32. Ba-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J. Exp. Med. 168:1988;1111-1125.
33. Furman P.A., Fyfe J.A., St. Clair M.H., Weinhold K., Rideut J.L., Freeman G.A., Lehrman S.N., Bolognesi D.P., Broder S., Mitsuya H., Barry D.W. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA. 83:1986;8333-8337.
34. Ono K., Nakane H., Herdewijn P., Balzarini J., De Clercq E. Differential inhibitory effects of several pyrimidine 2′,3′-dideoxynucleoside 5′-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases. Mol. Pharmacol. 35:1989;578-583.
35. St. Clair M.H., Richard C.A., Spector T., Weinhold K.j., Miller W.H., Langlois A.J., Furman P.A. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 31:1987;1972-1977.
36. Sommadossi J.-P., Carlisle R., Zhou Z. Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol. Pharmacol. 36:1989;9-14.
37. Harrington J.A., Reardon J.E., Spector T. 3′-azido-3′-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair AZT-terminated DNA. Antimicrob. Agents Chemother. 37:1993;918-920.
38. Bridges E.G., Faraj A., Sommadossi J.-P. Inhibition mammalian DNA polymerase-associated 3′-azido-3′-deoxythymidine and 3′-amino-3′-deoxythymidine. Biochem. Pharmacol. 45:1993;1571-1576.
39. Hall E.T., Yan J.-P., Melancon P., Kuchta R.D. 3′-Azido-3′-deoxythymidine potently inhibits protein glycosylation. J. Biol. Chem. 269:1994;14355-14358.
40. Yan J.-P., Ilsley D.D., Frohlick C., Steet R., Hall E.T., Kuchta R.D., Melanco P. 3′-Azidothymidine (zidovudine) inhibits glycosylation and dramatically alters glycosphingolipid synthesis in whole cells clinically relevant concentrations. J. Biol. Chem. 270:1995;22836-22841.
41. Lavie A., Vetter I.R., Konrad M., Goody R.S., Reinstein J., Schlichting I. Structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation. Nat. Struct. Biol. 4:1997;601-604.
42. Hartmann H., Vogt M.W., Durno A.G., Hirsch M.S., Hunsmann G., Eckstein F. Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogs. AIDS Res. Hum. Retroviruses. 4:1988;457-466.
43. Matthes E., Lehmann Ch., Scholz D., von Janta-Lipinski M., Gaertner K., Rosenthal H.A., Langen P. Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5′-triphosphate in comparison to cellular DNA α and β Biochem. Biophys. Res. Commun. 148:1987;78-85.
44. Matthes E., Lehmann Ch., Scholz D., Rosenthal H.A., Langen P. Phosphorylation, anti-HIV activity and cycotoxicity of 3′-fluorothymidine. Biochem. Biophys. Res. Commun. 153:1988;825-831.
45. Mansuri M.M., Hitchcock M.J.M., Buroker R.A., Bregman C.L., Ghazzouli I., Desiderio J.V., Starrett J.E., Sterzycki R.Z., Martin J.C. Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus. Antimicrob. Agents Chemother. 34:1990;637-641.
46. Kong X.-B., Zhu Q.-Y., Vidal P.M., Watanabe K.A., Polsky B., Armstrong D., Ostrander M., Lang S.A. Jr., Muchmore E., Chou T.-C. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 36:1992;808-818.
47. Lin T.-S., Schinazi R.F., Prusoff W.H. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′-deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem. Pharmacol. 36:1987;2713-2718.
48. Baba M., Pauwels R., Herdewijn P., De Clercq E., Desmyter J., Vandeputte M. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem. Biophys. Res. Commun. 142:1987;128-134.
49. Hamamoto Y., Nakashima H., Matsuda A., Ueda T., Yamamoto N. Inhibitory effect of 2′,3′-didehydro-2′,3′-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob. Agents Chemother. 31:1987;907-910.
50. Ho H.-T., Hitchcock M.J.M. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency. Antimicrob. Agents Chemother. 33:1987;844-849.
51. Balzarini J., Herdewijn P., De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264:1989;6127-6133.
52. Huang P., Farquhar D., Plunkett W. Selective action of 2′,3′-didehydro-2′,3′-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J. Biol. Chem. 267:1992;2817-2822.
53. August E.M., Birks E.M., Prusoff W.H. 3′-Deoxythymidin-2′-ene permeation of human lymphocyte cells by non-facilitated diffusion. Mol. Pharmacol. 39:1991;246-249.
54. Mansuri M.M., Starrett J.E. Jr., Ghazzouli I., Hitchcock M.J.M., Sterzycki R.Z., Brankovan V., Lin T.-S., August E.M., Prosoff W.H., Sommadossi J.-P., Martin J.C. 1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine. A potent and selective anti-HIV agent. J. Med. Chem. 32:1989;461-466.
55. Zhu Z., Hitchcock M.J.M., Sommadossi J.P. Metabolism and DNA interaction of 2′,3′-didehydro-2′,3′-dideoxythymidine in human bone barrow cells. Mol. Pharmacol. 40:1991;838-845.
56. Collins J.M., Unadkat J.D. Clinical pharmacokinetics of zidovudine. Clin. Pharmacokinet. 17:1989;1-9.
57. Wilde M.I., Langtry H.D. Zidovudine. Drugs. 46:1993;515-578.
58. Klecker R.W. Jr., Collins J.M., Yarchoan R., Thomas R., Jenkins J.F., Broder S., Myers C.E. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin. Pharmacol. Ther. 41:1987;407-412.
59. Collins J.M., Klecker R.W. Jr., Kelly J.A., Roth J.S., McCully C.L., Balis F.M., Poplack D.G. Pyrimidine dideoxyribonucleosides: selective penetration into cerebrospinal fluid. J. Pharmacol. Exp. Ther. 245:1988;466-470.
60. Blum M.R., Lao S.H.T., Good S.S., deMiranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85:1988;S189-194.
61. Stagg M.P., Cretton E.M., Kidd L., Diasio R.B., Sommadossi J.-P. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin. Pharmacol. Ther. 51:1992;668-676.
62. Richman D.D., Fischl M.A., Grieco M.H., Gottlieb M.S., Volberding P.A., Laskin O.L., Leedom J.M., Groopman J., Mildvan D., Hirsch M.S., Jackson G.G., Durack D.T., Phil D., Nusinoff-Lehrman S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New Engl. J. Med. 317:1987;192-197.
63. Lietamn P.S. Lessons learned from pharmacodynamic studies of anti-HIV drugs. Antiviral Res. 20:(Suppl. 1):1993;22.
64. Boudinot F.D., Smith S.G., Fundergurg E.D., Schinazi R.F. Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′,3′-didehydrothymidine in rats. Antimicrob. Agents Chemother. 35:1991;747-749.
65. Schinazi R.F., Boudinot F.D., Doshi K.J., McClure H.M. Pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-deoxy-2′,3′-didehydrothymidine in rhesus monkeys. Antimicrob. Agents Chemother. 34:1990;1214-1219.
66. Lea A.P., Faulds D. Stavudine. Drugs. 51:1996;846-864.
67. Rana K.Z., Dudley M.N. Clinical pharmacokinetics of stavudine. Clin. Pharmacokinet. 33:1997;276-284.
68. Dudley M.N., Graham K.K., Kaul S., Geletko S., Dunkle L., Browne M., Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166:1992;480-485.
69. Browne M.J., Mayer K.H., Chafee S.B.D., Dudley M.N., Posner M.R., Steinberg S.M., Graham K.K., Geletko S.M., Zinner S.H., Denman S.L., Dunckle L.M., Kaul S., McLaren C., Skowron G., Kouttab N.M., Kennedy T.A., Weitberg A.B., Curt G.A. 2′,3′-Didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J. Infect. Dis. 167:1993;21-29.
70. Eriksson B.F.H., Chu C.K., Schinazi R.F. Phosphorylation of 3′-azido-2′,3′-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptase by its 5′-triphosphate. Antimicrob. Agents Chemother. 33:1989;1729-1734.
71. Schinazi R.F., Lloyd R., Oswald B., Manning C. Effect of AZT, AZddU, FDT, and BCH-189 nucleosides on DNA chain termination mediated by HIV-1 reverse transcriptase. Fourth International Conference on Antiviral Research :1991;International Society for Antiviral Research, New Orleans, LA.
72. Schinazi R.F., Chu C.K., Ahn M.K., Sommadossi J.-P. Selective in vitro inhibition of human immunodeficiency virus (HIV) replication by 3′-azido-2′,3′-dideoxyuridine (CS-87). J. Cell Biochem. 11:(suppl. D):1987;405.
73. Zhu Z., Schinazi R.F., Chu C.K., Williams G.J., Colby C.B., Sommadosi J.-P. Cellular metabolism of 3′-azido-2′,3′-dideoxyuridine with formation of 5′-O-diphosphohexose derivative by previously unrecognized metabolic pathways for 2′-deoxyuridine analogs. Mol. Pharmacol. 38:1990;929-938.
74. Schinazi R.F., Mead J.R., Feorino P.M. Insights into HIV Chemotherapy. AIDS Res. Hum. Retroviruses. 8:1992;963-990.
75. Balzarini J., van Aerschot A., Pauwels R., Baba M., Schols D., Herdewijn P., De Clercq E. 5-Halogeno-3′-fluoro-2′,3′-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3′-fluoro-2′,3′-dideoxy-5-chlorouridine. Mol. Pharmacol. 35:1989;571-577.
76. Daluge S., Purifoy D.J.M., Savina P.M., St. Clair M.H., Parry N.R., Dev I.K., Novak P., Ayers K.M., Reardon J.E., Roberts G.B., Fyfe J.A., Blum M.B., Averett D.R., Dornsife R.E., Domin B.A., Ferone R., Lewis D.A., Krenitsky T.A. 5-Chloro-2′,3′-dideoxy-3′-flurouridine (93U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother. 38:1994;1590-1603.
77. Doshi K.J., Gallo J.M., Boudinot F.D., Schinazi R.F., Chu C.K. Comparative pharmacokinetics of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZddU) in mice. Drug Metab. Dispos. 17:1989;590-594.
78. Boudinot F.D., Schinazi R.F., Gallo J.M., McClure H.M., Anderson D.C., Doshi K.J., Kambhampathi P.C., Chu C.K. 3′-Azido-2′,3′-dideoxyuridine (AZddU): comparative pharmacokinetics with 3′-azido-3′-deoxythymidine (AZT) in monkeys. AIDS Res. Hum. Retroviruses. 6:1990;219-228.
79. Cooney D.A., Dalal M., Mitsuya H., McMahon J.B., Nadkarni M., Balzarini J., Broder S., Johns D.G. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem. Pharmacol. 35:1986;2065-2068.
80. Starnes M.C., Cheng Y.-C. Cellular metabolism of 2′,3′-dideoxycytidine, a compound against human immunodeficiency virus. J. Biol. Chem. 262:1987;988-991.
81. Chen C.-H., Cheng Y.-C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264:1989;11934-11937.
82. Lewis L.D., Hamzeh F.M., Lietman P.S. Ultrastructure changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:1992;2061-2065.
83. Lin T.-S., Luo M.-Z., Liu M.-C., Pai B., Dutschman G.E., Cheng Y.-C. Antiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus in vitro. Biochem. Pharmacol. 47:1994;171-174.
84. Gossenlin G., Schinazi R.F., Sommadossi J.-P., Mathe C., Bergogne M.-C., Aubertin A.-M., Kirn A., Imbach J.-L. Anti-human immunodeficiency virus activities of the β-L enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob. Agents Chemother. 38:1994;1292-1297.
85. Faraj A., Agrofoglio L.A., Wakefield J.K., McPherson S., Morrow C., Gosselin G., Mathe C., Imbach J.-L., Schinazi R.F., Sommadossi J.-P. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5′-triphosphate β enantiomers of cytidine analogs. Antimicrob. Agents Chemother. 38:1994;2300-2305.
86. Kukhanova M., Liu S.-H., Mozzherin D., Lin T.-S., Chu C.K., Cheng Y.-C. L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. J. Biol. Chem. 270:1995;23055-23059.
87. Bridges E.G., Dutschman G.E., Gullen E.A., Cheng Y.-C. Favorable interaction of β-L-(-)-nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem. Pharmacol. 51:1996;731-736.
88. Schinazi R.F., Chu C.K., Eriksson B.F., Sommadossi J.-P., Doshi K.J., Boudinot F.D., Oswald B., McClure H.M. Antiretroviral activity, biochemistry, and pharmacokinetics of 3′-azido-2′,3′-dideoxy-5-methylcytidine. Ann. New York Acad. Sci. 616:1990;385-397.
89. Devineni D., Gallo J.M. Zalcitabine. Clin. Pharmacokinet. 28:1995;351-360.
90. Adkins J.C., Peters D.H., Faulds D. Zalcitabine. Drugs. 53:1997;1054-1080.
91. Klecker R.W., Collins J.M., Yarchoan R.C., Thomas R., McAtee N., Broder S., Myers C.E. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. Clin. Pharmacol. 28:1988;837-842.
92. Gustavson L.E., Fukuda E.K., Rubio F.A., Dunton A.W. A pilot study of the bioavailability and pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS or AIDS-related complex. J. AIDS. 3:1990;28-31.
93. Kelly J.A., Litterst C.L., Roth J.S., Vistica D.T., Poplack D.G., Cooney D.A., Nadkarni M., Balis F.M., Broder S., Johns D.G. The disposition and metabolism of 2′,3′-dideoxycyticine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab. Dispos. 15:1987;595-601.
94. R. Yarchoan, C.F. Perno, R.V. Thomas, R.W. Klecker, J.-P. Allain, R.J. Wills, N. McAtee, M.A. Fischl, R. Dubinsky, M.C. McNeely, H. Mitsuya, J.M. Pluda, T. Lawley, M. Leuther, B. Safai, J.M. Collins, C.E. Myers, S. Broder, Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternative with zidovudine (AZT), Lancet (1988) 76-81.
95. Boudinot F.D., Ibrahim S.S., Qin Y., Chu C.K., Schinazi R.F. Pharmacokinetics of 3′-azido-2′,3′-dideoxy-5-methylcytidine in rats. Antiviral Chem. Chemother. 1:1990;367-371.
96. Boudinot F.D., Schinazi R.F., Doshi K.J., McClure H.M., Chu C.K. Pharmacokinetics and metabolism of 3′-azido-2′,3′-dideoxy-5-methylcytidine in rhesus monkeys. Drug Metab. Dispos. 21:1990;855-860.
97. Johnson M.A., Fridland A. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36:1989;291-295.
98. Ahluwalia G., Cooney D.A., Mitsuya H., Fridland A., Flora K.P., Hao Z., Dalal M., Broder S., Johns D.G. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor or HIV infectivity. Biochem. Pharmacol. 36:1987;3797-3800.
99. Johnson M.A., Ahluwalia g., Connelly M.c., Cooney D.A., Broder S., Johns D.G., Fridland A. Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. J. Biol. Chem. 263:1988;15354-15357.
100. Back D.J., Ormesher S., Tjia J.F., Macleod R. Metabolism of 2′,3′-dideoxyinosine (ddI) in human blood. Br. J. Clin. Pharmacol. 33:1992;319-322.
101. Ahluwalia G., Johnson M.A., Fridland A., Cooney D.A., Broder S., Johns D.G. Cellular pharmacology of the anti-HIV agent 2′,3′-dideoxyadenosine. Proc. Am. Acad. Cancer Res. 29:1988;349.
102. Marquez V.E., Tseng C.K.-H., Mitsuya H., Aoki S., Kelly J.A., Ford H. Jr., Roth J.S., Broder S., Johns D.G., Driscoll J.S. Acid-stable 2′-fluoro purine dideoxynucleosides as active agents against HIV. J. Med. Chem. 33:1990;978-985.
103. Masood R., Ahluwalia G.S., Cooney D.A., Fridland A., Marquez V.E., Driscoll J.S., Hao Z., Mitsuya H., Perno C.-F., Broder S., Johns D.G. 2′-Fluoro-2′,3′-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2′,3′-dideoxyadenosine. Mol. Pharmacol. 37:1990;590-596.
104. Ahluwalia G.S., Cooney D.A., Shirasaka T., Mitsuya H., Driscoll J.S., Johns D.G. Enhancement by 2′-deoxycoformycin of the 5′-phosphorylation and anti-human immunodeficiency virus activity of 2′,3′-dideoxyadenosine and 2′-β-2′,3′-fluoro-2′,3′-dideoxyadenosine. Mol. Pharmacol. 46:1994;1002-1008.
105. Nair V., St. Clair M.H., Reardon J.E., Krasny H.C., Hazen R.J., Paff M.T., Boone L.R., Tisdale M., Najera I., Dornsife R.E., Averett D.R., Borroto-Esoda K., Yale J.L., Zimmerman T.P., Rideout J.L. Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol. Antimicrob. Agents Chemother. 39:1995;1993-1999.
106. Hartman N.R., Yarchoan R., Pluda J.M., Thomas R.V., Marczyk K.S., Broder S., Johns D.G. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin. Pharmacol. Ther. 47:1990;647-654.
107. Perry C.M., Balfour J.A. Didanosine. Drugs. 52:1996;928-962.
108. Shyu W.C., Knupp C.A., Pittman K.A., Dunkle L., Barbhaiya R.H. Food-induced reduction in bioavailability of didanosine. Clin. Pharmacol. Ther. 50:1991;503-507.
109. Knupp C.A., Shyu W.C., Dolin R., Valentine F.T., McLaren C., Martin R.R., Pittman K.A., Barbhaiya R.H. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin. Pharmacol. Ther. 49:1990;523-535.
110. Rozencwig M., McLaren C., Beltangady M., Ritter J., Canetta R., Schacter L., Kelly S., Nicaise C., Smaldone L., Dunckle L., Barbhaiya R., Knupp C., Cross A., Tsianco M., Martin R.R. Overview of phase I trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Rev. Infect. Dis. 12:1990;S570-S575.
111. Yarchoan R., Mitsuya H., Pluda J.M., Marczyk K.S., Thomas R.V., Hartman N.R., Brouwers P., Perno C.-F., Allain J.-P., Johns D.G., Broder S. The National Cancer Institute phase I study of 2′,3′-dideoxyinosine administration in adults with AIDS or AIDS-related complex: Analysis of activity and toxicity. Rev. Infect. Dis. 12:1990;S522-S533.
112. Anderson B.D., Hoesterey B.L., Baker D.C., Galinsky R.E. Uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies. J. Pharmacol. Exp. Ther. 253:1990;113-118.
113. Singhal D., Morgan M.E., Anderson B.D. Role of altered metabolism in dideoxynucleoside pharmacokinetics. Drug Metab. Dispos. 24:1996;1155-1161.
114. Singhal D., Morgan M.E., Anderson B.D. Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2′-b-fluoro-2′,3′-dideoxyinosine and 2′-b-fluoro-2′,3′-dideoxyadenosine in rats. Pharm. Res. 14:1997;786-792.
115. Shanmuganathan K., Koudriakova T., Nampalli S., Du J., Gallo J.M., Schinazi R.F., Chu C.K. Enhanced brain delivery of an anti-HIV nucleoside 2′-F-ara-ddI by xanthine oxidase mediated biotransformation. J. Med. Chem. 37:1994;821-827.
116. Koudriakova T., Manouilov K.K., Shanmuganthan K., Kotra L.P., Boudinot F.D., Cretton-Scott E., Sommadossi J.-P., Schinazi R.F., Chu C.K. In vitro and in vivo evaluation of 6-azido-2′,3′-dideoxy-2′-fluoro-b-D-arabinofuranosylpurine and N6-methyl-2′,3′-dideoxy-2′-fluoro-b-D- arabinofuranosyladenosine as prodrugs of the anti-HIV nucleosides 2′-F-ara-ddA and 2′-F-ara-ddI. J. Med. Chem. 39:1996;4676-4681.
117. Anderson B.D., Galinsky R.E., Baker D.C., Chi S.-C., Hoesterey B.L., Morgan M.E., Murakami K., Mitsuya H. Approaches toward the optimization of CNS uptake of anti-AIDS agents. J. Control. Release. 19:1991;219-230.
118. Morgan M.E., Chi S.-C., Murakami K., Mitsuya H., Anderson B.D. Central nervous system targeting of 2′,3′-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs. Antimicrob. Agents Chemother. 36:1992;2156-2165.
119. Doshi K.J., Boudinot F.D., Gallo J.M., Schinazi R.F., Chu C.K. Brain targeting of anti-HIV nucleosides: in vitro and in vivo evaluation of 6-chloro-2′,3′-dideoxypurine, a lipophilic prodrug of 2′,3′-dideoxyinosine. Antiviral Chem. Chemother. 5:1994.
120. Schinazi R.F., Chu C.K., Peck A., McMillan A., Mathis R., Cannon D., Jeong L.-S., Beach J.W., Choi W.-B., Yeola S., Liotta D.C. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob. Agents Chemother. 36:1992;672-676.
121. Schinazi R.F., McMillan A., Cannon D., Mathis R., Lloyd R.M., Peck A., Sommadossi J.-P., St. Clair M., Wilson J., Furman P.A., Painter G., Choi W.-B., Liotta D.C. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:1992;2423-2431.
122. Soudeyns H., Yao X.-J., Gao Q., Belleau B., Kraus J.-L., Nguyen-Ba N., Spira B., Wainberg M.A. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob. Agents Chemother. 35:1991;1386-1390.
123. Coates J.A.V., Cammack N., Jenkinson H.J., Mutton I.M., Pearson B.B., Storer R., Cameron J.M., Penn C.R. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob. Agents Chemother. 36:1992;202-205.
124. Coates J.A.V., Cammack N., Jenkinson H.J., Jowett A.J., Jowett M.I., Pearson B.A., Penn C.R., Rouse P.L., Viner K.C., Cameron J.M. (-)-2′-3′-Thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:1992;733-739.
125. Cammack N., Rouse P., Marr C.L.P., Reid P.J., Boehme R.E., Coates J.A.V., Penn C.R., Cameron J.M. Cellular metabolism of (-)-enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:1992;2059-2064.
126. Chang C.-N., Skalski V., Zhou J.H., Cheng Y.-C. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 267:1992;22414-22420.
127. Gray N.M., Marr C.L.P., Penn C.R., Cameron J.M., Bethell R.C. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase γ Biochem. Pharmacol. 50:1995;1043-1051.
128. Kewn S., Veal G.J., Hoggard P.G., Barry M.G., Back D.J. Lamivudine (3TC) phosphorylation and drug interaction in vitro. Biochem. Pharmacol. 54:1997;589-595.
129. Furman P.A., Davis M., Liotta D.C., Paff M., Frick L.W., Nelson D.J., Dornsife R.E., Wurster J.A., Wilson L.J., Fyfe J.A., Tuttle J.V., Miller W.H., Condreay L., Averett D.R., Schinazi R.F., Painter G.R. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-)- and (+)-enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:1992;2686-2692.
130. Perry C.M., Faulds D. Lamivudine. Drugs. 53:1997;657-680.
131. van Leeuwen R., Lange J.M.A., Hussey E.K., Donn K.H., Hall S.T., Harker A.J., Jonker P., Danner S.A. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 6:1992;1471-1475.
132. van Leeuwen R., Katlama C., Kitchen V., Boucher C.A.B., Tubiana R., McBride M., Ingrand D., Weber J., Hill A., McDade H., Danner S.A. Evaluation of safety of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 171:1995;1166-1171.
133. Pluda J.M., Cooley T.P., Montaner J.S.G., Shay L.E., Reinhalter N.E., Warthan S.N., Ruedy J., Hirst H.M., Vicary C.A., Quinn J.B., Yuen G.J., Waingerg M.A., Rubin M., Yarchoan R. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171:1995;1438-1447.
134. Schinazi R.F., Boudinot F.D., Imbrahim S.S., Manning C., McClure H.M., Liotta D.C. Pharmacokinetics and metabolism of racemic 2′,3′-dideoxy-5-fluoro-3′-thiacytidine in rhesus monkeys. Antimicrob. Agents Chemother. 36:1992;2432-2438.
135. Kim H.O., Ahn S.K., Alves A.J., Beach J.W., Jeong L.S., Choi B.G., Van Roey P., Schinazi R.F., Chu C.K. Asymmetric synthesis of 1,3-dioxolane-pyrimidine nucleosides and their anti-HIV activity. J. Med. Chem. 35:1992;1987-1995.
136. Kim H.O., Schinazi R.F., Shanmuganathan K., Jeong L.S., Beach J.W., Nampalli S., Cannon D.L., Chu C.K. L-β-(2S,4S)-and L-α-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationship. J. Med. Chem. 36:1993;519-528.
137. Kim H.O., Schinazi R.F., Nampalli S., Shanmuganathan K., Cannon D.L., Alves A.J., Jeong L.S., Beach J.W., Chu C.K. 1,3-Dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. J. Med. Chem. 36:1993;30-37.
138. Kim H.O., Shanmuganathan K., Alves A.J., Jeong L.S., Beach J.W., Schinazi R.F., Chang C.-N., Cheng Y.-C., Chu C.K. Potent anti-HIV and anti-HBV activities of (-)-L-β-dioxolane-C-and (+)-L-β-dioxolane-T and their asymmetric syntheses. Tetrahedron Lett. 33:1992;6899-6902.
139. Schinazi R.F., Gosselin G., Faraj A., Korba B.E., Liotta D., Chu C.K., Mathe C., Imbach J.-L., Sommadossi J.-P. Pure nucleoside enantiomers of β-2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 38:1994;2172-2174.
140. Grove K.L., Guo X., Liu S.-H., Gao Z., Chu C.K. Anticancer activity of β-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res. 55:1995;3008-3011.
141. Grove K.L., Cheng Y.-C. Uptake and Metabolism of the new anticancer compound β-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res. 56:1996;4187-4191.
142. Kukhanova M., Liu S.-H., Mozzherin D., Lin T.-S., Chu C.K., Cheng Y.-C. L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. J. Biol. Chem. 270:1995;23055-23059.
143. Rajagopalan P., Boudinot F.D., Chu C.K., Tennant B.C., Baldwin B.H., Schinazi R.F. Pharmacokinetics of (-)-β-D-2,6-diaminopurine dioxolane and its metabolite, dioxolane guanosine, in woodchucks (Marmota monax). Antiviral Chem. Chemother. 7:1996;65-70.
144. Chen H., Boudinot F.D., Chu C.K., McClure H.M., Schinazi R.F. Pharmacokinetics of (-)-β-D-2-aminopurine dioxolane and (-)-β-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-β-D-dioxolane guanine in rhesus monkeys. Antimicrob. Agents Chemother. 40:1996;2332-2336.
145. Manouilov K.K., Manouilova L.S., Boudinot F.D., Schinazi R.F., Chu C.K. Biotransformation and pharmacokinetics of prodrug 9-(β-D-1,3-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(β-D-1,3-dioxolan-4-yl)guanine in mice. Antiviral Res. 35:1997;187-193.
146. Bennett L.L. Jr., Shannon W.M., Allan P.W., Arnett G. Studies on the biochemical activities of some nucleoside analogs. Ann. New York Acad. Sci. 255:1975;342-358.
147. Vince R., Hua M., Brownell J., Daluge S., Lee F., Shannon W.M., Lavelle G., Qualls J., Weislow O.S., Kiser R., Canonico P.G., Schultz R.H., Narayanan V.L., Mayo J.G., Shoemaker R.H., Boyd M.R. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem. Biophys. Res. Commun. 156:1988;1046-1053.
148. Vince R., Hua M. Synthesis and anti-HIV activity of carbocyclic 2′,3′-didehydro-2′,3′-dideoxy-2,6-disubstituted purine nucleosides. J. Med. Chem. 33:1990;17-21.
149. Bondoc L.L. Jr., Shannon W.M., Secrist J.A. III, Vince R., Fridland A. Metabolism of the carbocyclic nucleoside analogue carbovir, an inhibitor of human immunodeficiency virus, in human lymphoid cells. Biochemistry. 29:1990;9839-9843.
150. White E.L., Parker W.B., Macy L.J., Shaddis S.C., McCaleb G., Secrist J.A. III, Vince R., Shannon W.M. Comparison of the effect of carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem. Biophys. Res. Commun. 161:1989;393-398.
151. Parker W.B., White E.L., Shaddix S.C., Rose L.J., Buckheit R.W. Jr., Germany J.M., Secrist J.A. III, Vince R., Shannon W.M. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases α, β, and γ by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine, and 3′-deoxythymidine. J. Biol. Chem. 266:1991;1754-1762.
152. Carter S.G., Kessler J.A., Rankin C.D. Activities of (-)-carbovir and 3′-azido-3′-deoxythymidine against human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 34:1990;1297-1300.
153. Miller W.A., Daluge S., Garvey E.P., Hopkins S., Reardon J.E., Boyd F.L., Miller R.L. Phosphorylation of carbovir enantiomers by cellular enzymes determines the stereoselectivity of antiviral activity. J. Biol. Chem. 267:1992;21220-21224.
154. Mahony W.B., Domin B.A., Daluge S., Miller W.H., Zimmerman T.P. Enantiomeric selectivity of carbovir transport. J. Biol. Chem. 267:1992;19792-19797.
155. Orr D.C., Figueiredo H.T., Mo C.-L., Penn C.R., Cameron J.M. DNA chain termination activity and inhibition of human immunodeficiency virus reverse transcriptase by carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine triphosphate. J. Biol. Chem. 267:1992;4177-4182.
156. Parker W.B., Shaddix S., Bowdon B.J., Rose L.M., Vince R., Shannon W.M., Bennett L.L. Jr. Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism. Antimicrob. Agents Chemother. 37:1993;1004-1009.
157. Parker W.B., Shaddix S., Vince R., Bennett L.L. Jr. Lack of mitochondrial toxicity in CEM cells treated with carbovir. Antiviral Res. 34:1997;131-136.
158. Faletto M.B., Miller W.H., Garvey E.P., St. Clair M.H., Daluge S.M., Good S.S. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41:1997;1099-1107.
159. Daluge S., Good S.S., Faletto M.B., Miller W.H., St. Clair M.H., Boone L.R., Tisdale M., Parry N.R., Reardon J.E., Dornsife R.E., Averett D.R., Krenitsky T.A. 1592U89, a novel carbocyclic nucleoside analog with potent selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1997;1082-1093.
160. Yeom Y.H., Remmel R.P., Huang S.-H., Hua M., Vince R., Zimmerman C.L. Pharmacokinetics and bioavailability of carbovir, a carbocyclic nucleoside active against human immunodeficiency virus, in rats. Antimicrob. Agents Chemother. 33:1989;171-175.
161. El Dareer S.M., Tillery K.F., Rose L.M., Struck R.F., Hill D.L. Disposition and metabolism of carbovir in mice dosed intravenously or orally. Drug Metab. Dispos. 18:1990;842-845.
162. Brouwer K.R., St. Clair R.L., Lagarde J., Patanella J.E., Walsh J.S., Miwa G.T. The pharmacokinetics of (-)-carbovir in rats. Drug Metab. Dispos. 18:1990;1078-1083.
163. Walsh J.S., Patanella J.E., Unger S.E., Brouwer K.R., Miwa G.T. The metabolism and excretion of carbovir, a carbocyclic nucleoside in the rat. Drug Metab. Dispos. 18:1990;1084-1091.
164. Zimmerman C.L., Iyer K.R., Faudskar II A.L., Remmel R.P. Glucuronidation as a transient intermediate metabolic step in the elimination of (-)-carbovir. Drug Metab. Dispos. 21:1993;902-910.
165. Patanella J.E., Walsh J.S., Unger S.E., Miwa G.T., Parry P.S., Daniel M.J., Evans G.L. Identification of a glucuronide conjugate of the carbocyclic nucleoside, carbovir, isolated from marmoset urine. Drug Metab. Dispos. 18:1990;1092-1095.
166. Yeager R.L., Brouwer K.R., Miwa G.T. (-)-6-Aminocarbovir pharmacokinetics and relative carbovir exposure in rats. Drug Metab. Dispos. 19:1991;462-466.
167. Zimmerman C.L., Remmel R.P., Ibrahim S.S., Geers S.A., Vince R. Pharmacokinetic evaluation of (-)-6-aminocarbovir as a prodrug for (-)-carbovir in rats. Drug Metab. Dispos. 20:1992;47-51.
168. Wen Y.-D., Remmel R.P., Pham P.T., Vince R., Zimmerman C.L. Comparative brain exposure to (-)-carbovir after (-)-carbovir intravenous infusion in rats. Pharm. Res. 12:1995;911-915.
169. Good S.S., Owens B.S., Faletto M.B., Mahony W.B., Domin B.A. Disposition in monkeys and mice of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, a potent inhibitor of HIV. Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy :1994;American Society for Microbiology, Orlando, Florida. abstr. I86.
170. Ching S.V., Ayers K.M., Dornsife R.E., Lewis D., Grebe G.L., Howard J.L. Nonclinical toxicology and in vitro toxicity studies with the novel anti-HIV Agent (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9yl]-2-cyclopentene-1-methanol (1592U89) succinate. Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy :1994;American Society for Microbiology, Orlando, Florida. abstr. I88.
171. Pauwels R., Balzarini J., Schols D., Baba M., Desmyter J., Rossenberg I., Holy A., De Clercq E. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32:1988;1025-1030.
172. Kim C.U., Luh B.Y., Misco P.F., Bronson J.J., Hitchcock M.J.M., Ghazzouli I., Martin J.C. Acyclic purine phosphonate analogues as antiviral agents. Synthesis and structure relationships. J. Med. Chem. 33:1990;1207-1213.
173. Balzarini J., Holy A., Jindrich J., Dvorakova H., Hao A., Snoeck R., Herdewijn P., Johns D.G., De Clercq E. 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 88:1991;4961-4965.
174. Balzarini J., Holy A., Jindrich J., Naesens L., Snoeck R., Schols D., De Clercq E. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37:1993;332-338.
175. Balzarini J., Aquaro S., Perno C.-F., Witvrouw M., Holy A., De Clercq E. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem. Biophys. Res. Commun. 219:1996;337-341.
176. Miyasaka T., Tanaka H., Baba M., Hayakawa H., Walker R.T., Balzarini J., De Clercq E. A novel lead for specific anti-HIV-1 agents: 1-[2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32:1989;2507-2509.
177. Baba M., De Clercq E., Tanaka H., Ubasawa M., Takashima H., Sekiya K., Nitta I., Umezu K., Nakashima H., Mori S., Shigeta S., Walker R.T., Miyasaka T. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA. 88:1991;2356-2360.
178. Goudgaon N.M., Schinazi R.F. Activity of acyclic 6-(phenylselenenyl)pyrimidine nucleosides against human immunodeficiency viruses in primary lymphocytes. J. Med. Chem. 34:1991;3305-3309.
179. H. Tanaka, M. Baba, S. Saito, T. Miyasaka, H. Takashima, K. Sekiya, M. Ubasawa, I. Nitta, R.T. Walker, H. Nakashima, E. De Clercq, Specific anti-HIV-1 'acyclonucleosides': which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine, J. Med. Chem. (1991) 1508-1511.
180. Tanaka H., Takashima H., Ubassawa M., Sekiya K., Nitta I., Baba M., Shigeta S., Walker R.T., De Clercq E., Miyasaka T. Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 35:1992;4713-4719.
181. Balzarini J., Naesens L., Herdewijn P., Rosenberg I., Holy A., Pauwels R., Baba M., Johns D.G., De Clercq E. Marked in vivo antiretrovus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc. Natl. Acad. Sci. USA. 86:1989;332-336.
182. Smith M.S., Brian E.L., De Clercq E., Pagano J.S. Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 33:1989;1482-1486.
183. Smith M.S., Brian E.L., De Clercq E., Pagano J.S. Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic adenosine analogs and synergy of the analogs with 3′-azido-3′-deoxythymidine. Biochem. Pharmacol. 44:1989;2067-2077.
184. Palu G., Stefanelli S., Rassu M., Parolin C., Balzarini J., De Clercq E. Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antiviral Res. 16:1991;115-119.
185. Balzarini J., Hao Z., Herdewijn P., Johns D.G., De Clercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. USA. 88:1991;1499-1503.
186. Merta A., Votruba I., Jindrich J., Holy A., Cihlar T., Rosenberg I., Otmar M., Herve T. Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP(dAMP) kinase from L1210 cells. Biochem. Pharmacol. 44:1992;2067-2077.
187. Balzarini J., Perno C.-F., Schols D., De Clercq E. Activity of acyclic nucleoside phosphonate against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 178:1991;329-335.
188. Naesens L., Balzarini J., De Clercq E. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine. Drug Metab. Dispos. 20:1992;747-752.
189. Balzarini J., Naessens L., Slachmuylders J., Niphuis H., Rosenberg I., Holy A., Schellekens H., De Clercq E. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS. 5:1991;21-28.
190. Doshi K.J., Islam Q., Gallo J.M., Boudinot F.D., Hsieh L., Qin Y., Schinazi R.F., Chu C.K. Brain targeting of anti-HIV nucleosides: ether prodrugs of 3′-azido-2′,3′-dideoxyuridine (AZdU) and 3′-azido-3′-deoxythymidine. Antiviral Chem. Chemother. 4:1993;263-269.
191. Tortolani D.R., Russell J.W., Whiterock V.J., Hitchcock M.J.M., Ghazzouli I., Martin J.C., Mansuri M.M., Starrett J.E. Jr. Prodrugs of 2′,3′-didehro-3′-deoxythymidine (D4T): synthesis, antiviral activity, and rapid pharmacokinetic evaluation. J. Pharm. Sci. 83:1994;339-343.
192. Ibrahim S.S., Boudinot F.D., Schinazi R.F., Chu C.K. Physicochemical properties, bioconversion and disposition of lipophilic prodrugs of 2′,3′-dideoxycytidine. Antiviral Chem. Chemother. 7:1996;167-172.
193. Hostetler K.Y., Stuhmiller L.M., Lenting H.B.M., van den Bosch H., Richman D.D. Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides. J. Biol. Chem. 265:1990;6112-6117.
194. Hostetler K.L., Carson D.A., Richman D.D. Phosphatidylazidothymidine. J. Biol. Chem. 266:1991;11714-11717.
195. van Wijk G.M.T., Hostetler K.Y., Schlame M., van den Bosch H. Cytidine diphosphate diglyceride analogs of antiretroviral dideoxynucleosides: evidence for release of dideoxynucleoside-monophosphates by phospholipid biosynthetic enzymes in rat liver subcellular fractions. Biochim. Biophys. Acta. 1086:1991;99-105.
196. van Wijk G.M.T., Hostetler K.Y., van de Bosch H. Lipid conjugates of antiretroviral agents: release of antiretroviral nucleoside monophosphates by a nucleoside diphosphate diglyceride hydrolase activity from rat liver mitochondrial. Biochim. Biophys. Acta. 1084:1991;307-310.
197. Hostler K.Y., Richman D.D., Carson D.A., Stuhmiller L.M., van de Wijk G.M.T., van de Bosch H. Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3′-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3′-deoxythymidine. Antimicrob. Agents Chemother. 36:1992;2025-2029.
198. Hostler K.Y., Richman D.D., Sridhar C.N., Felgner P.L., Felgner J., Ricci J., Gardner M.F., Selleseth D.W., Ellis M.N. Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in rauscher leukemia virus-infected mice. Antimicrob. Agents Chemother. 38:1994;2792-2797.
199. Manouilov K.K., Fedorov I.I., Boudinot F.D., White C.A., Kotra L.P., Schinazi R.F., Hong C.I., Chu C.K. Lymphatic targeting of anti-HIV nucleosides: distribution of 3′-azido-3′-deoxythymidine (AZdU) after administration of dipalmitoylphosphatidyl prodrugs to mice. Antiviral Chem. Chemother. 6:1995;2230-2238.
200. Manouilov K.K., Xu Z.-S., Manouilova L.S., Boudinot F.D., Schinazi R.F., Chu C.K. Lymphatic targeting of anti-human immunodeficiency virus nucleosides: pharmacokinetics of 3′-deoxy-2′,3′-didehydrothymidine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug to mice. Antiviral Chem. Chemother. 8:1997;409-415.
201. Manouilov K.K., Xu Z.-S., Boudinot F.D., Schinazi R.F., Chu C.K. Lymphatic targeting of anti-HIV nucleosides: distribution of 2′,3′-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice. Antiviral Res. 34:1997;91-99.
202. Torrence P.F., Kinjo J.-E., Lesiak K., Balzarini J., De Clercq E. AIDS dementia: synthesis and properties of a derivative of 3′-azido-3′-deoxythymidine (AZT) that may become 'locked' in the central nervous system. FEBS Lett. 234:1988;135-140.
203. Gogu S.R., Aggarwal S.K., Rangan S.R.S., Agrawal K.C. A pro-drug of zidovudine with enhanced efficacy against human immunodeficiency virus. Biochem. Biophys. Res. Commun. 160:1989;656-661.
204. C.K. Chu, V.S. Bhadti, K.J. Doshi, J.T. Etse, J.M. Gallo, F.D. Boudinot, R.F. Schinazi, Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyrimidine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-3′-deoxythymidine, J. Med. Chem. (1990) 2188-2192.
205. Palomino E., Kessel D., Horwitz J.P. A dihydropyridine carrier system for sustained delivery of 2′,3′-dideoxynucleosides to brain. J. Med. Chem. 32:1989;622-625.
206. Torrence P.F., Kinjo J.-E., Khamnei S., Greig N.H. Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the antiimmunodeficiency virus agent dideoxycytidine. J. Med. Chem. 36:1993;529-537.
207. Starrett J.E. Jr., Tortolani D.R., Russel J., Hitchcock M.J.M., Valerie W., Martin J.C., Mansuri M.M. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethyoxy)ethyl]adenosine (PMEA). J. Med. Chem. 37:1994;1857-1864.
208. Sastry J.A., Nehete P.N., Khan S., Nowak B.J., Plunkett W., Arlinghaus R.B., Farquhar D. Membrane-permeable dideoxyuridine 5′-monophosphate analogue inhibits human immunodeficiency virus infection. Mol. Pharmacol. 41:1992;441-445.
209. Srinivas R.V., Robbins B.L., Connelly M.C., Gong Y.-F., Bischofberger N., Fridland A. Metabolism and in vitro antiretroviral activities of bis(POM) prodrugs of acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 37:1993;2247-2250.
210. Curley D., McGuigan C., Devine K.G., O'Connor T.J., Jeffries D.J., Kinchington D. Synthesis and anti-HIV evaluation of some phosphoramidate derivatives of AZT: Studies on the effect of chain elongation on biological activity. Antiviral Res. 14:1990;345-356.
211. McGuigan C., Devine K.G., O'Connor T.J., Kinchington D. Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3′-azido-3′-deoxythymidine (AZT): potent activity of the trichloroethyl methoxyalaninyl compound. Antiviral Res. 15:1991;255-263.
212. McGuigan C., Pathirana R.N., Mahmood N., Devine K.G., Hay A.J. Aryl phosphate derivatives of AZT retain activity against HIV 1 in cell lines which are resistant to the action of AZT. Antiviral Res. 17:1992;311-321.
213. McGuigan C., Tsang H.-W., Cahard D., Turner K., Velazquez S., Salgado A., Bidois L., Naesens L., De Clercq E., Balzarini J. Phosphoramidate derivatives of d4T as inhibitors of HIV: The effect of amino acid variation. Antiviral Res. 35:1997;195-204.
214. McGuigan C., Pathirana R.N., Balzarini J., De Clercq E. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. J. Med. Chem. 36:1993;1048-1052.
215. Balzarini J., Wedgwood O., Kruining J., Pelemans H., Heijtink R., De Clercq E., McGuigan C. Anti-HIV and Anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem. Biophys. Res. Commun. 225:1996;363-369.
216. McGuigan C., Cahard D., Sheeka H.M., De Clercq E., Balzarini J. Phosphoramidate derivatives of d4T with improved anti-HIV efficacy retain full activity in thymidine kinase-deficient cells. Bioorg. Med. Chem. Lett. 6:1996;1183-1186.
217. McGuigan C., Wedgwood O.M., De Clercq E., Balzarini J. Phosphoramidate derivatives of 2′,3′-didehydro-2′,3′-dideoxyadenosine [d4A] have markedly improved anti-HIV potency and selectivity. Bioorg. Med. Chem. Lett. 6:1996;2359-2362.
218. Balzarini J., Kruning J., Wedgwood O., Pannecouque C., Aquaro S., Perno C.-F., Naesens L., Witvrouw M., Heijtink R., De Clercq E., McGuigan C. Conversion of 2′,3′-dideoxyadenosine (ddA) and 2′,3′-didehydro-2′,3′-dideoxyadenosine (d4A) to their corresponding aryloxyphophoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus. FEBS Lett. 410:1997;324-328.
219. Puech F., Gosselin G., Lefebvre I., Pompon A., Aubertin M., Kirn A., Imbach J.-L. Intracellular delivery of monophosphates through a reductase-mediated activation process. Antiviral Res. 22:1993;155-174.
220. Perigaud C., Aubertin A.-M., Benzaria S., Pelicano H., Girardet J.-L., Maury G., Gosselin G., Kirn A., Imbach J.-L. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3-dideoxythymidine. Biochem. Pharmacol. 48:1994;11-14.
221. Valette G., Pompon A., Girardet J.-L., Cappellacci L., Franchetti P., Grifantini M., Colla P.L., Loi A.G., Perigaud C., Gosselin G., Imbach J.-L. Decomposition pathways and in vitro HIV inhibitory effects of isoddA pronucleotides. J. Med. Chem. 39:1996;1981-1990.
222. Lefebvre I., Perigaud C., Pompon A., Aubertin A.-M., Girardet J.-L., Kirn A., Gosselin G., Imbach J.-L. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioconversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3-dideoxythymidine 5′-monophosphate. J. Med. Chem. 38:1995;3941-3950.
223. Thuman-Schweitzer C., Gosselin g., Perigaud c., Benzaria S., Girardet J.-L., Lefebvre I., Imbach J.-L., Kirn A., Aubertin A.-M. Anti-human immunodeficiency virus type 1 activities of dideoxynucleoside phosphotriester derivatives in primary monocytes/macrophages. Res. Virol. 147:1996;155-163.
224. Benzaria S., Pelicano H., Johnson R., Maury G., Imbach J.-L., Aubertin A.-M., Obert G., Gosselin G. Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. J. Med. Chem. 39:1996;4958-4965.
225. Perigaud C., Girardet J.-L., Lefebvre I., Xie M.-Y., Aubertin A.-M., Kirn A., Gosselin G., Imbach J.-L., Sommadossi J.-P. Comparison of cytotoxicity of mononucleoside phosphotriester derivatives bearing biolabile phosphate protecting groups in normal human bone marrow progenitor cells. Antiviral Chem. Chemother. 7:1996;338-345.
226. Balzarini J., Karlsson A., Aquaro S., Perno C.-F., Cahard D., Naesens L., De Clercq E., McGuigan C. Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives. Proc. Natl. Acad. Sci. USA. 93:1996;7295-7299.
227. McGuigan C., Cahard D., Sheeka H.M., De Clercq E., Balzarini J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J. Med. Chem. 39:1996;1748-1753.
228. Cundy K.C., Fishback J.A., Shaw J.-P., Lee M.L., Soike K.F., Visor G.C., Lee W.A. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm. Res. 11:1994;839-843.
229. Naesens L., Neyts J., Balzarini J., Bischofberger N., De Clercq E. In vivo antiretroviral efficacy of oral bis(POM)-PMEA, the bis(pivaloyloxymethyl)prodrug of 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Nucleosides Nucleotides. 14:1995;767-770.
230. Naesens L., Balzarini J., Bischofberger N., De Clercq E. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 40:1996;22-28.
231. X. Tan, C.K. Chu, D. Egron, C. Perigaud, G. Gosselin, J.-L. Imbach, F.D. Boudinot, Intracellular delivery of AZT monophosphate (AZTMP): pharmacokinetic studies of AZT and UA428-a bispivaloylthioethyl prodrug of AZTMP, in mice, Pharm. Sci. 1 (Suppl.), S-681, AAPS Thirteenth Annual Meeting, San Francisco, CA, November, 1998.
232. S.-H. Huang, C.K. Chu, D. Egron, C. Perigaud, G. Gosselin, J.-L. Imbach, F.D. Boudinot, Lymphatic targeting of 3′-Azido-2′,3′-dideoxyuridine (AzdU) after administration of Bispivalothioethyl Prodrug to Mice, Pharm. Sci. 1 (Suppl.), S-670, AAPS Thirteenth Annual Meeting, San Francisco, CA, November, 1998.
233. Busso M., Mian A.M., Hahn E.F., Resnick L. Nucleotide dimers suppress HIV expression in vitro. AIDS Res. Hum. Retroviruses. 4:1988;449-455.
234. Schinazi R.F., Sommadossi J.-P., Saalmann V., Cannon D.L., Xie M.-Y., Hart G., Smith G.A., Hahn E.F. Antimicrob. Agents Chemother. 34:1990;1061-1067.
235. 4-lymphocytes. Biochem. Pharmacol. 40:1990;2603-2610.
236. Henin Y., Gouyette C., Schwartz O., Debouzy J.-C., Neumann J.-M., Huynh-Dinh T. Lipophilic glycosyl phosphotriester derivatives of AZT: synthesis, NMR transmembrane transport study, and antiviral activity. J. Med. Chem. 34:1991;1830-1837.
237. Lorey M., Meier C., De Clercq E., Balzarini J. New synthesis and antitumor activity of cycloSal-derivatives of 5-fluoro-2′-deoxyuridinemonophosphate. Nucleosides Nucleotides. 16:1997;789-792.
238. Meier C., De Clercq E., Balzarini J. Cyclo-saligenyl-3′-azido-2′,3′-dideoxythymidinemonophosphate (cyclosal-AZTMP)-a new pro-nucleotide approach. Nucleosides Nucleotides. 16:1997;739-796.
239. Meier C., Lorey M., De Clercq E., Balzarini J. Cyclo-saligenyl-2′,3′-dideoxy-2′,3′- didehydrothymidinemonophosphate (cyclosal-d4TMP)-a new pro-nucleotide approach. Nucleosides Nucleotides. 16:1997;1303-1306.